North Chicago-based Abbott announced last month it reached a settlement agreement with Dexcom over all outstanding patent disputes relating to their glucose monitoring products, which estimate blood ...

Progress in medicine could lead to a smaller target market for DexCom. However, the company is expanding opportunities through innovation. On the other hand, DexCom has attractive opportunities ...

In this article, we are going to take a look at where Dexcom, Inc. (NASDAQ ... almost the same as the government spends on the entire Medicare program. That's a staggering figure.

Wells Fargo notes Abbott (ABT) and DexCom (DXCM) have disclosed that on December 20, they settled and entered into a cross-license agreement to resolve all outstanding patent litigation in the U.S ...

DexCom stock slumped 40% to $64.70 in trading ... which sells competing glucose monitors, among Medicare patients. The slump in new patient sign-ups led to an utter collapse for the stock, which ...

Additionally, the accelerating shift of some Medicare Advantage patients from DME to pharmacy channels adds complexity to DexCom's channel strategy. The company will need to demonstrate that it ...

Dec 23 (Reuters) - Abbott Laboratories (ABT.N), opens new tab and DexCom (DXCM.O), opens new tab said on Monday they have reached an agreement to settle all patent disputes between them related to ...

The applications of generative artificial intelligence (GenAI) have reached continuous glucose monitoring after DexCom launched rolled out the technology into its glucose biosensor products.

Dexcom (DXCM) stock is down over 40% in Friday's session after the continuous glucose monitoring technology company fell short of revenue estimates for its second quarter and slashed its full-year ...